- Home
- SUPN vs EFSC Comparison
SUPN vs EFSC Comparison
Compare SUPN & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- EFSC
- Stock Information
- Founded
- SUPN 2005
- EFSC 1988
- Country
- SUPN United States
- EFSC United States
- Employees
- SUPN N/A
- EFSC N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- EFSC Major Banks
- Sector
- SUPN Health Care
- EFSC Finance
- Exchange
- SUPN Nasdaq
- EFSC Nasdaq
- Market Cap
- SUPN 2.0B
- EFSC 2.2B
- IPO Year
- SUPN 2012
- EFSC 1999
- Fundamental
- Price
- SUPN $35.66
- EFSC $57.77
- Analyst Decision
- SUPN Hold
- EFSC Strong Buy
- Analyst Count
- SUPN 1
- EFSC 4
- Target Price
- SUPN $36.00
- EFSC $56.50
- AVG Volume (30 Days)
- SUPN 285.1K
- EFSC 152.9K
- Earning Date
- SUPN 11-04-2024
- EFSC 01-21-2025
- Dividend Yield
- SUPN N/A
- EFSC 1.88%
- EPS Growth
- SUPN 130.79
- EFSC N/A
- EPS
- SUPN 1.07
- EFSC 4.72
- Revenue
- SUPN $651,972,000.00
- EFSC $591,631,000.00
- Revenue This Year
- SUPN $7.82
- EFSC N/A
- Revenue Next Year
- SUPN N/A
- EFSC $0.15
- P/E Ratio
- SUPN $34.11
- EFSC $12.65
- Revenue Growth
- SUPN 6.79
- EFSC N/A
- 52 Week Low
- SUPN $25.53
- EFSC $37.28
- 52 Week High
- SUPN $39.37
- EFSC $63.13
- Technical
- Relative Strength Index (RSI)
- SUPN 48.87
- EFSC 49.59
- Support Level
- SUPN $35.68
- EFSC $58.14
- Resistance Level
- SUPN $37.35
- EFSC $59.97
- Average True Range (ATR)
- SUPN 1.01
- EFSC 1.24
- MACD
- SUPN -0.18
- EFSC -0.41
- Stochastic Oscillator
- SUPN 21.65
- EFSC 16.20
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate, and consumer loans.